Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II

scientific article published on 01 June 1988

Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID2836060

P2093author name stringLiu LF
Grossberg H
Hsiang YH
Kirschenbaum S
Potmesil M
Bank B
Kanganis D
Forlenza TJ
Penziner A
P433issue12
P407language of work or nameEnglishQ1860
P304page(s)3537-3543
P577publication date1988-06-01
P1433published inCancer ResearchQ326097
P1476titleResistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II
P478volume48

Reverse relations

cites work (P2860)
Q41396887"Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
Q36614847A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
Q54291944Absence of correlation between cytotoxicity and drug transport by P-glycoprotein in clinical leukemic cells
Q40388183Anthracycline antibiotics in cancer therapy. Focus on drug resistance
Q55033660Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Q36466122Biochemical pharmacology of anthracenediones and anthrapyrazoles
Q36617921CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues
Q40880283Clinical pharmacokinetics of irinotecan
Q28343739Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells
Q36135365Differential expression of the topoisomerase II alpha and beta genes in human breast cancers
Q35763155Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Q35158232Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer
Q24554531Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin
Q30656004Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data
Q36710645Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II.
Q72538851Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features
Q37256902Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast
Q24554360Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
Q37467770Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.
Q33495553Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration
Q44025370Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy
Q54220320Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Q28591946Targeted disruption of the mouse topoisomerase I gene by camptothecin selection
Q33500497The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
Q40028536Topoisomerase I inhibitors and drug resistance
Q40694357Topoisomerase expression in cancer cell lines and clinical samples
Q40499871Topoisomerase inhibitors. A review of their therapeutic potential in cancer

Search more.